In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.3, denoting a -4.44% move from the preceding trading day.
Tilray Brands, Inc. (TLRY) concluded the recent trading session at $4.5, signifying a -1.53% move from its prior day's close.
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.72, denoting a -2.48% move from the preceding trading day.
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.48, denoting a -4.07% move from the preceding trading day.
Tilray Inc (NASDAQ:TLRY) is making progress in its transition into a diversified consumer products company, according to Jefferies, which reiterated its ‘Buy' rating while lowering its price target to $19 from a higher prior target after cutting earnings forecasts. Shares traded up almost 3% at about $4 on Thursday afternoon The firm reduced its fiscal 2027 and 2028 EBITDA estimates after management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million, below the consensus estimate of $84 million.
Tilray Brands stock continued its strong downtrend and is hovering at its lowest level since June last year. TLRY has slumped by 57% this year, mirroring the performance of other cannabis stocks like Green Thumb Industries, Truelive Cannabis, and Curaleaf.
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.2 per share a year ago.
Tilray Brands NASDAQ: TLRY reported record fiscal 2026 revenue and adjusted EBITDA, supported by growth in international cannabis, pharmaceutical distribution, wellness and the fourth-quarter acquisition of BrewDog.
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $4.23, moving 1.63% from the previous trading session.
Tilray Brands, Inc. (TLRY) closed at $4.38 in the latest trading session, marking a -1.79% move from the prior day.
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $4.31, moving 1.6% from the previous trading session.
Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.